Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company is headquartered in Wuxi, the People's Republic of China.
| Revenue (TTM) | $2.54M |
| Gross Profit (TTM) | $2.41M |
| EBITDA | $-5.21M |
| Operating Margin | -76.50% |
| Return on Equity | -113.00% |
| Return on Assets | -50.70% |
| Revenue/Share (TTM) | $11.82 |
| Book Value | $8.75 |
| Price-to-Book | 0.39 |
| Price-to-Sales (TTM) | 0.87 |
| EV/Revenue | 0.0085 |
| EV/EBITDA | 15.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.50% |
| Shares Outstanding | 747,900 |
| Float | 269,340 |
| % Insiders | 30.29% |
| % Institutions | 0.20% |
Volatility is currently expanding
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH) (NASDAQ: BYAH) between December 27, 2024 and July 8, 2025, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
BYAH CFO Xiaoyan Zhu since 2016 signed the December 2024 registration statement that the lawsuit contends omitted the promotional scheme behind BYAH's 93% stock collapse. NEW YORK, Sept.
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
A securities class action traces a seven-month sequence from Park Ha Biological Technology Co., Ltd.'s December 2024 public debut at $4.00 per share to its July 2025 surge above $41.49, followed by a 93% single-session collapse to $2.99 on July 8, 2025, which erased more than $1 billion in market value without any company announcement.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Park Ha Biological Technology Co., Inc., (“Park Ha” or the "Company") (NASDAQ: PHH) investors of a class action on behalf of investors that bought securities between Dec 27, 2024 – Jul 8, 2025, inclusive (the “Class Period”). Park Ha investors have until September 28, 2026 to file a lead plaintiff motion.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
Retail investors funneled into WhatsApp groups were told BYAH would climb 200% to 300% on a rumored L'Oréal partnership; instead the stock fell 93% in one session, and the lawsuit contends the Company never disclosed the promotional scheme driving its shares. Retail investors funneled into WhatsApp groups were told BYAH would climb 200% to 300% on a rumored L'Oréal partnership; instead the stock fell 93% in one session, and the lawsuit contends the Company never disclosed the promotional scheme driving its shares.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BYAH and any ticker you trade — then tracks every position and per-strategy win rate.
